Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Holstein, SA; Hohl, RJ
   Interaction of cytosine arabinoside and lovastatin in human leukemia cells
   LEUKEMIA RESEARCH
   
   S.A. Holstein e R.J. Hohl, "Interaction of cytosine arabinoside and lovastatin in human leukemia cells", LEUK RES, 25(8), 2001, pp. 651-660
2. Chapel, S; Veng-Pedersen, P; Hohl, RJ; Schmidt, RL; McGuire, EM; Widness, JA
   Changes in erythropoietin pharmacokinetics following busulfan-induced bonemarrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway
   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
   
   S. Chapel et al., "Changes in erythropoietin pharmacokinetics following busulfan-induced bonemarrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway", J PHARM EXP, 298(2), 2001, pp. 820-824
3. Karp, JE; Lancet, JE; Kaufmann, SH; End, DW; Wright, JJ; Bol, K; Horak, I; Tidwell, ML; Liesveld, J; Kottke, TJ; Ange, D; Buddharaju, L; Gojo, I; Highsmith, WE; Belly, RT; Hohl, RJ; Rybak, ME; Thibault, A; Rosenblatt, J
   Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
   BLOOD
   
   J.E. Karp et al., "Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial", BLOOD, 97(11), 2001, pp. 3361-3369
4. Cermak, DM; Wiemer, DF; Lewis, K; Hohl, RJ
   2-(acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: Synthesis and biological characterization
   BIOORGANIC & MEDICINAL CHEMISTRY
   
   D.M. Cermak et al., "2-(acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: Synthesis and biological characterization", BIO MED CH, 8(12), 2000, pp. 2729-2737
5. Jung, KY; Hohl, RJ; Wiemer, AJ; Wiemer, DF
   Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside
   BIOORGANIC & MEDICINAL CHEMISTRY
   
   K.Y. Jung et al., "Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside", BIO MED CH, 8(10), 2000, pp. 2501-2509
6. Yung, WKA; Albright, RE; Olson, J; Fredericks, R; Fink, K; Prados, MD; Brada, M; Spence, A; Hohl, RJ; Shapiro, W; Glantz, M; Greenberg, H; Selker, RG; Vick, NA; Rampling, R; Friedman, H; Phillips, P; Bruner, J; Yue, N; Osoba, D; Zaknoen, S; Levin, VA
   A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
   BRITISH JOURNAL OF CANCER
   
   W.K.A. Yung et al., "A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse", BR J CANC, 83(5), 2000, pp. 588-593
7. Burns, CP; Halabi, S; Clamon, GH; Hars, V; Wagner, BA; Hohl, RJ; Lester, E; Kirshner, JJ; Vinciguerra, V; Paskett, E
   Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B study 9473
   CLINICAL CANCER RESEARCH
   
   C.P. Burns et al., "Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B study 9473", CLIN CANC R, 5(12), 1999, pp. 3942-3947
8. HOLSTEIN SA; CERMAK DM; WIEMER DF; LEWIS K; HOHL RJ
   PHOSPHONATE AND BISPHOSPHONATE ANALOGS OF FARNESYL PYROPHOSPHATE AS POTENTIAL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
   Bioorganic & medicinal chemistry
   
   S.A. Holstein et al., "PHOSPHONATE AND BISPHOSPHONATE ANALOGS OF FARNESYL PYROPHOSPHATE AS POTENTIAL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE", Bioorganic & medicinal chemistry, 6(6), 1998, pp. 687-694
9. GAO F; HOHL RJ; SHIRES TK
   GERANYLGERANIOL RESTORES CELL-GROWTH AND RAS PROCESSING IN MEVALONATE-DEPLETED FIBROBLAST CELLS
   The FASEB journal
   
   F. Gao et al., "GERANYLGERANIOL RESTORES CELL-GROWTH AND RAS PROCESSING IN MEVALONATE-DEPLETED FIBROBLAST CELLS", The FASEB journal, 12(5), 1998, pp. 4325-4325
10. HOHL RJ; SHERBURNE AR; FEELEY JE; HUISMAN THJ; BURNS CP
    LOW PULSE OXIMETER-MEASURED HEMOGLOBIN OXYGEN SATURATIONS WITH HEMOGLOBIN CHEVERLY
    American journal of hematology
    
    R.J. Hohl et al., "LOW PULSE OXIMETER-MEASURED HEMOGLOBIN OXYGEN SATURATIONS WITH HEMOGLOBIN CHEVERLY", American journal of hematology, 59(3), 1998, pp. 181-184
11. HOHL RJ; LEWIS KA; CERMAK DM; WIEMER DF
    STEREOCHEMISTRY-DEPENDENT INHIBITION OF RAS FARNESYLATION BY FARNESYLPHOSPHONIC-ACIDS
    Lipids
    
    R.J. Hohl et al., "STEREOCHEMISTRY-DEPENDENT INHIBITION OF RAS FARNESYLATION BY FARNESYLPHOSPHONIC-ACIDS", Lipids, 33(1), 1998, pp. 39-46
12. HOHL RJ; LEWIS KA; GUSTIN DM
    EFFECTS OF PERILLYL ALCOHOL ON RAS EXPRESSION IN HUMAN BLADDER-CANCERAND MONONUCLEAR BLOOD-CELLS
    Clinical pharmacology and therapeutics
    
    R.J. Hohl et al., "EFFECTS OF PERILLYL ALCOHOL ON RAS EXPRESSION IN HUMAN BLADDER-CANCERAND MONONUCLEAR BLOOD-CELLS", Clinical pharmacology and therapeutics, 63(2), 1998, pp. 3-3
13. LEWIS KA; HOHL RJ
    MODULATION OF RAS EXPRESSION IN HUMAN-MALIGNANT CELLS BY DIETARY-SUPPLEMENTS
    Nutrition
    
    K.A. Lewis e R.J. Hohl, "MODULATION OF RAS EXPRESSION IN HUMAN-MALIGNANT CELLS BY DIETARY-SUPPLEMENTS", Nutrition, 13(10), 1997, pp. 921-923
14. HOHL RJ; POGATCHNIK DM; LEWISTIBESAR K; WIEMER DF
    DIFFERENTIAL INHIBITION OF FARNESYL-PROTEIN TRANSFERASE AND SQUALENE SYNTHASE BY ISOPRENOID PHOSPHONIC-ACIDS
    Clinical pharmacology and therapeutics
    
    R.J. Hohl et al., "DIFFERENTIAL INHIBITION OF FARNESYL-PROTEIN TRANSFERASE AND SQUALENE SYNTHASE BY ISOPRENOID PHOSPHONIC-ACIDS", Clinical pharmacology and therapeutics, 61(2), 1997, pp. 27-27
15. HOHL RJ; LEWISTIBESAR K; POGATCHNIK DM; WIEMER DF
    DIFFERENTIAL-EFFECTS OF ISOPRENOID PHOSPHONIC-ACIDS ON RAS FARNESYLATION AND CHOLESTEROL-SYNTHESIS
    Journal of investigative medicine
    
    R.J. Hohl et al., "DIFFERENTIAL-EFFECTS OF ISOPRENOID PHOSPHONIC-ACIDS ON RAS FARNESYLATION AND CHOLESTEROL-SYNTHESIS", Journal of investigative medicine, 44(7), 1996, pp. 342-342
16. THIBAULT A; SAMID D; TOMPKINS AC; FIGG WD; COOPER MR; HOHL RJ; TREPEL J; LIANG B; PATRONAS N; VENZON DJ; REED E; MYERS CE
    PHASE-I STUDY OF LOVASTATIN, AN INHIBITOR OF THE MEVALONATE PATHWAY, IN PATIENTS WITH CANCER
    Clinical cancer research
    
    A. Thibault et al., "PHASE-I STUDY OF LOVASTATIN, AN INHIBITOR OF THE MEVALONATE PATHWAY, IN PATIENTS WITH CANCER", Clinical cancer research, 2(3), 1996, pp. 483-491
17. PETERS C; MILLER J; ABEL SL; MCMILLAN SK; GETCHELL JP; GILLER RH; HOHL RJ; DEALARCON PA
    IOWA NEWBORN HEMOGLOBINOPATHY SCREENING AND COMPREHENSIVE CARE - A MODEL FOR RURAL STATES
    Journal of pediatric hematology/oncology
    
    C. Peters et al., "IOWA NEWBORN HEMOGLOBINOPATHY SCREENING AND COMPREHENSIVE CARE - A MODEL FOR RURAL STATES", Journal of pediatric hematology/oncology, 18(4), 1996, pp. 416-418
18. LEE CK; HARMAN GS; HOHL RJ; GINGRICH RD
    FATAL CYCLOPHOSPHAMIDE CARDIOMYOPATHY - ITS CLINICAL COURSE AND TREATMENT
    Bone marrow transplantation
    
    C.K. Lee et al., "FATAL CYCLOPHOSPHAMIDE CARDIOMYOPATHY - ITS CLINICAL COURSE AND TREATMENT", Bone marrow transplantation, 18(3), 1996, pp. 573-577
19. HOHL RJ; POGATCHNIK DM; LEWISTIBESAR K; WIEMER DF
    INHIBITION OF RAS FARNESYLATION BY ISOPRENOID PHOSPHONIC-ACIDS
    Clinical pharmacology and therapeutics
    
    R.J. Hohl et al., "INHIBITION OF RAS FARNESYLATION BY ISOPRENOID PHOSPHONIC-ACIDS", Clinical pharmacology and therapeutics, 59(2), 1996, pp. 39-39
20. GOLDMAN F; HOHL RJ; CRABTREE J; LEWISTIBESAR K; KORETZKY G
    LOVASTATIN INHIBITS T-CELL ANTIGEN RECEPTOR SIGNALING INDEPENDENT OF ITS EFFECTS ON RAS
    Blood
    
    F. Goldman et al., "LOVASTATIN INHIBITS T-CELL ANTIGEN RECEPTOR SIGNALING INDEPENDENT OF ITS EFFECTS ON RAS", Blood, 88(12), 1996, pp. 4611-4619
21. LEE CK; GINGRICH RD; HARMAN GS; HOHL RJ; SVSEL IA; FRANCY RJ; AJRAM KA; JOHANNSEN SM
    GRAFT-VERSUS-HOST DISEASE AND SURVIVAL IN GRADED INCREMENTAL ADD-BACK(GIAB) FOR T-CELL DEPLETION-ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT), COMPARED TO 2-LEVEL ADD-BACK (TLAB)
    Blood
    
    C.K. Lee et al., "GRAFT-VERSUS-HOST DISEASE AND SURVIVAL IN GRADED INCREMENTAL ADD-BACK(GIAB) FOR T-CELL DEPLETION-ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT), COMPARED TO 2-LEVEL ADD-BACK (TLAB)", Blood, 88(10), 1996, pp. 3777-3777
22. BUNTINAS RL; LEWISTIBESAR K; POGATCHNIK DM; WIEMER DF; HOHL RJ
    ALTERATIONS OF RAS EXPRESSION IN HUMAN LEUKEMIA-CELLS INDUCED BY FARNESYL PYROPHOSPHATE ANALOGS
    Blood
    
    R.L. Buntinas et al., "ALTERATIONS OF RAS EXPRESSION IN HUMAN LEUKEMIA-CELLS INDUCED BY FARNESYL PYROPHOSPHATE ANALOGS", Blood, 88(10), 1996, pp. 822-822
23. LEE CK; GINGRICH RD; HARMAN GS; HOHL RJ; SYSEL IA; FRANCY RJ; AJRAM KA; JOHANNSEN SM
    RISK FACTOR-DEPENDENT MODULATION OF GRAFT-VERSUS-HOST DISEASE (GVHD) BY GRADED INCREMENTAL T-CELL ADD-BACK (GIAB) IN T-CELL DEPLETION ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT)
    Blood
    
    C.K. Lee et al., "RISK FACTOR-DEPENDENT MODULATION OF GRAFT-VERSUS-HOST DISEASE (GVHD) BY GRADED INCREMENTAL T-CELL ADD-BACK (GIAB) IN T-CELL DEPLETION ALLOGENEIC BONE-MARROW TRANSPLANTATION (TCD-AL-BMT)", Blood, 88(10), 1996, pp. 1662-1662
24. LEE CK; GINGRICH RD; HARMAN GS; HOHL RJ
    TBI-BVAC, AN EFFECTIVE ALLOGENEIC ABLATIVE REGIMEN FOR LYMPHOMA AND MULTIPLE-MYELOMA
    Blood
    
    C.K. Lee et al., "TBI-BVAC, AN EFFECTIVE ALLOGENEIC ABLATIVE REGIMEN FOR LYMPHOMA AND MULTIPLE-MYELOMA", Blood, 88(10), 1996, pp. 2461-2461
25. LEE CK; GINGRICH RD; HOHL RJ; AJRAM KA
    ENGRAFTMENT SYNDROME IN AUTOLOGOUS BONE-MARROW AND PERIPHERAL STEM-CELL TRANSPLANTATION
    Bone marrow transplantation
    
    C.K. Lee et al., "ENGRAFTMENT SYNDROME IN AUTOLOGOUS BONE-MARROW AND PERIPHERAL STEM-CELL TRANSPLANTATION", Bone marrow transplantation, 16(1), 1995, pp. 175-182
26. CLAMON GH; RIGGS CE; DREICER R; HOHL RJ
    PHASE-II TRIAL OF EDATREXATE IN PATIENTS WITH METASTATIC COLORECTAL-CANCER
    Investigational new drugs
    
    G.H. Clamon et al., "PHASE-II TRIAL OF EDATREXATE IN PATIENTS WITH METASTATIC COLORECTAL-CANCER", Investigational new drugs, 13(4), 1995, pp. 359-361
27. HOHL RJ; LEWIS K
    DIFFERENTIAL-EFFECTS OF MONOTERPENES AND LOVASTATIN ON RAS PROCESSING
    The Journal of biological chemistry
    
    R.J. Hohl e K. Lewis, "DIFFERENTIAL-EFFECTS OF MONOTERPENES AND LOVASTATIN ON RAS PROCESSING", The Journal of biological chemistry, 270(29), 1995, pp. 17508-17512
28. HOHL RJ; LEWIS K
    PLASMA LOVASTATIN BIOACTIVITY AFTER HIGH-DOSE THERAPY FOR MALIGNANCY IN HUMANS
    Clinical pharmacology and therapeutics
    
    R.J. Hohl e K. Lewis, "PLASMA LOVASTATIN BIOACTIVITY AFTER HIGH-DOSE THERAPY FOR MALIGNANCY IN HUMANS", Clinical pharmacology and therapeutics, 57(2), 1995, pp. 175-175
29. GINGRICH RD; LEE CK; WEN BC; HOHL RJ; HARMAN GS; AJRAM KA
    A PILOT-STUDY OF AUTOLOGOUS MARROW BLOOD STEM-CELL TRANSPLANTATION INTHE TREATMENT NONMETASTATIC INFLAMMATORY BREAST-CANCER/
    Blood
    
    R.D. Gingrich et al., "A PILOT-STUDY OF AUTOLOGOUS MARROW BLOOD STEM-CELL TRANSPLANTATION INTHE TREATMENT NONMETASTATIC INFLAMMATORY BREAST-CANCER/", Blood, 86(10), 1995, pp. 1529-1529
30. LEE CK; GINGRICH RD; HARMAN GS; HOHL RJ; AIRAM KA; PADLEY DJ; HULING DA; TRIGG ME
    ANTI-CD3 (OKT3) T-CELL DEPLETION AND ADD-BACK (TCD-AB) - COMPARATIVE-ANALYSIS WITH ANTI-CD2 (CT2) TCD-AB IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
    Blood
    
    C.K. Lee et al., "ANTI-CD3 (OKT3) T-CELL DEPLETION AND ADD-BACK (TCD-AB) - COMPARATIVE-ANALYSIS WITH ANTI-CD2 (CT2) TCD-AB IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)", Blood, 86(10), 1995, pp. 2266-2266
31. LEE CK; HARMAN GS; HOHL RJ; AJRAM KA; GINGRICH RD
    EFFECTS OF T-CELL DOSE AND GVHD ON IMMUNE RECONSTITUTION IN CD2 T-CELL DEPLETION AND 2-LEVEL ADD-BACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
    Blood
    
    C.K. Lee et al., "EFFECTS OF T-CELL DOSE AND GVHD ON IMMUNE RECONSTITUTION IN CD2 T-CELL DEPLETION AND 2-LEVEL ADD-BACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION", Blood, 86(10), 1995, pp. 2268-2268
32. LEE CK; HAYASHI M; HARMAN GS; HOHL RJ; AJRAM KA; GINGRICH RD
    ANTI-CD2 T-CELL DEPLETION WITH 2-LEVEL T-CELL ADDBACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT)
    Blood
    
    C.K. Lee et al., "ANTI-CD2 T-CELL DEPLETION WITH 2-LEVEL T-CELL ADDBACK (TCD-AB) IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (AL-BMT)", Blood, 86(10), 1995, pp. 2269-2269
33. HOHL RJ; LEWISTIBESAR K
    TARGETING THE ISOPRENOID PATHWAY FOR ANTILEUKEMIA THERAPY IN HUMANS
    Blood
    
    R.J. Hohl e K. Lewistibesar, "TARGETING THE ISOPRENOID PATHWAY FOR ANTILEUKEMIA THERAPY IN HUMANS", Blood, 86(10), 1995, pp. 3039-3039
34. SYSEL IA; LEE CK; FRANEY RJ; HARMAN GS; HOHL RJ; GINGRICH RD
    PULMONARY VENOOCCLUSIVE DISEASE (PVOD) IN THE ADULT BONE-MARROW TRANSPLANT POPULATION - 2 CASE-REPORTS
    Blood
    
    I.A. Sysel et al., "PULMONARY VENOOCCLUSIVE DISEASE (PVOD) IN THE ADULT BONE-MARROW TRANSPLANT POPULATION - 2 CASE-REPORTS", Blood, 86(10), 1995, pp. 3856-3856
35. HOHL RJ; LEWIS K; CLAMON G; KNAPP H
    CLINICAL-PHARMACOLOGY OF HIGH-DOSE LOVASTATIN
    Clinical research
    
    R.J. Hohl et al., "CLINICAL-PHARMACOLOGY OF HIGH-DOSE LOVASTATIN", Clinical research, 42(3), 1994, pp. 10000394-10000394
36. HOHL RJ; LEWIS K; KNAPP HR
    PHARMACODYNAMIC EFFECTS OF IN-VIVO LOVASTATIN ON HUMAN LEUKEMIA-CELLS
    Clinical pharmacology and therapeutics
    
    R.J. Hohl et al., "PHARMACODYNAMIC EFFECTS OF IN-VIVO LOVASTATIN ON HUMAN LEUKEMIA-CELLS", Clinical pharmacology and therapeutics, 55(2), 1994, pp. 189-189
37. GOLDMAN FD; HOHL RJ; CRABTREE J; KORETZKY G
    EFFECTS OF LOVASTATIN ON T-CELL SIGNALING
    Blood
    
    F.D. Goldman et al., "EFFECTS OF LOVASTATIN ON T-CELL SIGNALING", Blood, 84(10), 1994, pp. 10000227-10000227
38. PETERS C; MILLER J; ABEL SL; MCMILLAN SK; GETCHEL JP; GILLER RH; HOHL RJ; DEALARCON PA
    IOWA NEWBORN HEMOGLOBINOPATHY (HBP) SCREENING AND COMPREHENSIVE CARE - A MODEL FOR RURAL
    Blood
    
    C. Peters et al., "IOWA NEWBORN HEMOGLOBINOPATHY (HBP) SCREENING AND COMPREHENSIVE CARE - A MODEL FOR RURAL", Blood, 84(10), 1994, pp. 10000261-10000261
39. LEE CK; GINGRICH RD; HOHL RJ
    A DISTINCTIVE CLINICAL SYNDROME ACCOMPANYING THE ENGRAFTMENT PROCESS IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT)
    Blood
    
    C.K. Lee et al., "A DISTINCTIVE CLINICAL SYNDROME ACCOMPANYING THE ENGRAFTMENT PROCESS IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT)", Blood, 84(10), 1994, pp. 10000490-10000490
40. LEE CK; GINGRICH RD; HOHL RJ
    EFFECT OF STEROID FOR THE ENGRAFTMENT SYNDROME IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) ON SURVIVAL OF CHEMOSENSITIVE TUMORS AND IMMUNE RECONSTITUTION
    Blood
    
    C.K. Lee et al., "EFFECT OF STEROID FOR THE ENGRAFTMENT SYNDROME IN AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) ON SURVIVAL OF CHEMOSENSITIVE TUMORS AND IMMUNE RECONSTITUTION", Blood, 84(10), 1994, pp. 10000713-10000713
41. HOHL RJ; LEWIS K; KNAPP HR
    BIOACTIVITY OF LOVASTATIN IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    Clinical research
    
    R.J. Hohl et al., "BIOACTIVITY OF LOVASTATIN IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA", Clinical research, 41(3), 1993, pp. 10000661-10000661